Prostate tissue androgens: history and current clinical relevance.
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.
Circulating microRNAs as stable blood-based markers for cancer detection.
Proceedings of the National Academy of Science
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Journal of Pathology
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers: The Canary Prostate Cancer Tissue Microarray.
Adv Anat Pathol., Jan;20(1):39-44 (2013)
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
Nat. Med., Sep;18(9):1359-68 (2012)
VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.
Cancer Discov., Oct;2(10):906-21 (2012)
Urology., Jul;80(1):180-1; author reply 181 (2012)
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Cancer Res., Jul;72(14):3457-62 (2012)
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.
J. Clin. Endocrinol. Metab., Aug;97(8):2809-17 (2012)
Molecular pathways: involving microenvironment damage responses in cancer therapy resistance.
Clin. Cancer Res., Aug;18(15):4019-25 (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Nat. Genet., Jun;44(6):685-9 (2012)
Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts.
PLoS ONE., 7(4):e35876 (2012)
Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
J. Proteome Res., May;11(5):2653-65 (2012)
The monoamine oxidase A gene promoter repeat and prostate cancer risk.
Prostate., Nov;72(15):1622-7 (2012)
Androgen action and metabolism in prostate cancer.
Mol. Cell. Endocrinol., Sep;360(1-2):3-13 (2012)
Cellular senescence and cancer chemotherapy resistance.
Drug Resist. Updat., 15(1-2):123-31 (2012 Feb-Apr)
The androgen/androgen receptor axis in prostate cancer.
Curr Opin Oncol., May;24(3):251-7 (2012)
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.
J. Clin. Oncol., Feb;30(6):644-6 (2012)